parallel randomized trial
S003427
Type 2 diabetes (adults)S003427
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Liraglutide flexible dose injection once daily Ctrl group: conventional treatment plus liraglutide | conventional treatment, not described; lifestyle: not reported | 74 | ||
| A2 | Semaglutide 1.0 mg subcutaneous once weekly Obs group: conventional treatment plus semaglutide | conventional treatment, not described; lifestyle: not reported | 74 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Liraglutide flexible dose injection once daily A1 | Semaglutide 1.0 mg subcutaneous once weekly A2 |
|---|---|---|---|
| age | mean (years) | 52.23 | 53.19 |
| age | sd (years) | 3.19 | 3.25 |
| bmi | mean (kg/m2) | 26.77 | 27.26 |
| bmi | sd (kg/m2) | 4.16 | 4.56 |
| diabetes duration | mean (years) | 6.73 | 5.23 |
| diabetes duration | sd (years) | 1.14 | 1.61 |
| female | n | 36 | 34 |
| hba1c | mean (percent) | 9.93 | 10.11 |
| hba1c | sd (percent) | 3.29 | 2.19 |
| sbp | mean (mmHg) | 140.12 | 139.91 |
| sbp | sd (mmHg) | 10.13 | 11.62 |
Analyses this trial contributes to
- Level 2 or 3 hypoglycemia (participants)Type 2 diabetes (adults); longest follow-up; network meta-analysis
- Level 2 or 3 hypoglycemia (participants)Type 2 diabetes (adults); longest follow-up; network meta-analysis
- DiarrheaType 2 diabetes (adults); longest follow-up; network meta-analysis
- DiarrheaType 2 diabetes (adults); longest follow-up; network meta-analysis
Results
14 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (4 lines; O01)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 52.14 | A1 | change | -3.26 percent | 1.27 | not stated; other; R0044046:Results and Discussion | ||
| 52.14 | A1 | final | 6.67 percent | 2.11 | not stated; other; R0044046:Results and Discussion | ||
| 52.14 | A2 | change | -4.11 percent | 1.30 | not stated; other; R0044046:Results and Discussion | ||
| 52.14 | A2 | final | 6.00 percent | 2.09 | not stated; other; R0044046:Results and Discussion |
Level 2 or 3 hypoglycemia (participants) (2 lines; O04)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 3 / 74 | not stated; other; R0044046:Table IV | ||||
| A2 | events | 3 / 74 | not stated; other; R0044046:Table IV |
Systolic blood pressure change (4 lines; O05)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 52.14 | A1 | change | -8.6 mmHg | 2.18 | not stated; other; R0044046:Results and Discussion | ||
| 52.14 | A1 | final | 131.52 mmHg | 7.29 | not stated; other; R0044046:Results and Discussion | ||
| 52.14 | A2 | change | -16.82 mmHg | 7.22 | not stated; other; R0044046:Results and Discussion | ||
| 52.14 | A2 | final | 123.09 mmHg | 10.37 | not stated; other; R0044046:Results and Discussion |
Nausea (2 lines; O27A)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 2 / 74 | not stated; other; nausea and vomiting; R0044046:Table IV | ||||
| A2 | events | 3 / 74 | not stated; other; nausea and vomiting; R0044046:Table IV |
Diarrhea (2 lines; O27C)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 2 / 74 | not stated; other; R0044046:Table IV | ||||
| A2 | events | 3 / 74 | not stated; other; R0044046:Table IV |